ClinicalTrials.gg
CompletedNCT00419744Updated Sep 16, 2010Results posted

A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD

A Phase 3 interventional study of Budesonide/formoterol (SYMBICORT) pMDI and Formoterol Turbuhaler in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 140 sites in 9 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2010-09-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. formoterol · Pulmonary Disease, Chronic Obstructive.

Enrollment
14th of 89
1,200 · median 120
Started
2007
with 4 others
Phase 3
40 of 89
1 open now
Registered
16th of 89
by date
Lead sponsor
20 of 89
AstraZeneca

Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, this one is the 14th largest by enrollment, is one of 5 that started in 2007, is one of 40 in phase 3, and was the 16th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About formoterol

formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to determine if SYMBICORT® delivered via a pressurized metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A current clinical diagnosis of with COPD symptoms for more than 2 years
  • Current smoker or smoking history of 10 or more pack years (1 pack year = 20 cigarettes smoked per day for one year)
  • A history of at least 1 COPD exacerbations requiring a course of and/or antibiotics within 1-12 months before the first visit

Exclusion criteria

Exclusion Criteria:

  • A history of asthma at or after 18 years of age
  • A history of allergic rhinitis at or after 18 years of age
  • Subjects taking oral
  • Any significant disease or disorder that may jeopardize a subject's safety
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
1,200 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Total Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient-treatment Year

    Number of COPD-related exacerbations per patient-treatment year. COPD-related exacerbation was defined as worsening COPD that required a course of oral steriods for treatment and/or hospitalization.

    Time frame: 12 months

  2. Rate of Exacerbations Per Subject-year

    Rate of exacerbations per subject-year

    Time frame: 12 months

Secondary outcomes

  1. Pre-dose Forced Expiratory Volume in 1 Second (FEV1)

    Change in pre-dose FEV1 from baseline to the average of the randomized treatment period, as calculated by averaging treatment period FEV1 values and subtracting the pre-dose value.

    Time frame: 12 months

  2. Morning Peak Expiratory Flow (PEF)

    Change in morning PEF from baseline to the average of the randomized treatment period, as calculated by averaging treatment period PEF values and subtracting the baseline morning PEF value.

    Time frame: 12 months

  3. Evening PEF

    Change in evening PEF from baseline to the average of the randomized treatment period, as calculated by averaging treatment period PEF values and subtracting the baseline evening PEF value.

    Time frame: 12 months

  4. Dyspnea Symptom Scores

    Change from baseline of Dyspnea symptoms evaluated using the breathlessness diary, a 5-point Likert-type scale, ranging from 0 to 4 with higher scores indicating a more severe manifestation of the Dyspnea symptom. Change from baseline was calculated by averaging treatment period Dyspnea scores and subtracting the baseline Dyspnea scores.

    Time frame: 12 months

  5. Use of Rescue Medication

    Change from baseline in the use of beta-2 agonists, as calculated by averaging treatment period inhalations per day and subtracting the baseline number of inhalations per day.

    Time frame: 12 months

  6. St. George's Respiratory Questionnaire (SGRQ) Score

    Change from baseline in the SGRQ overall score, as calculated by averaging treatment period SGRQ scores and subtracting the baseline SGRQ scores. The SGRQ contains 3 domains: Symptoms (distress due to respiratory symptoms, 8 questions), Activity (disturbance of physical activity, 16 questions), and Impacts (overall impact on daily life and well-being, 26 questions). Lower scores are associated with less severe symptoms.

    Time frame: 12 months

07

Results

Posted Sep 16, 2010

Participant flow

First patient randomized on 02 January 2007. The last patient completed study on 27 August 2009. The study randomized patients in the United States and Mexico (93 investigational sites), South America (48 investigational sites), and South Africa (20 investigational sites).

Participant flow — Overall Study
MilestoneSYM 160/4.5 X 2 BIDSYM 80/4.5 X 2 BIDFOR 4.5 X 2 BID
Started407408404
Completed290290271
Not completed117118133
Withdrew: Adverse event394050
Withdrew: Withdrawal by subject454952
Withdrew: Lost to follow-up8106
Withdrew: Protocol violation478
Withdrew: Randomized in error967
Withdrew: Moving out of state201
Withdrew: Physician decision1056
Withdrew: Spirometry mouthpiece issues012
Withdrew: Incorrect medication kit dispensed001

Outcome measures

PrimaryTotal Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient-treatment Year

Number of COPD-related exacerbations per patient-treatment year. COPD-related exacerbation was defined as worsening COPD that required a course of oral steriods for treatment and/or hospitalization.

Time frame:
12 months
Reported as:
Number · Exacerbations
Total Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient-treatment Year
ExacerbationsSYM 160/4.5 X 2 BIDSYM 80/4.5 X 2 BIDFOR 4.5 X 2 BID
Total Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient-treatment Year0.750.841.14
SecondaryPre-dose Forced Expiratory Volume in 1 Second (FEV1)

Change in pre-dose FEV1 from baseline to the average of the randomized treatment period, as calculated by averaging treatment period FEV1 values and subtracting the pre-dose value.

Time frame:
12 months
Reported as:
Mean · Liters (L)
Pre-dose Forced Expiratory Volume in 1 Second (FEV1)
Liters (L)SYM 160/4.5 X 2 BIDSYM 80/4.5 X 2 BIDFOR 4.5 X 2 BID
Pre-dose Forced Expiratory Volume in 1 Second (FEV1)0.07 ± 0.180.07 ± 0.170.04 ± 0.17
SecondaryMorning Peak Expiratory Flow (PEF)

Change in morning PEF from baseline to the average of the randomized treatment period, as calculated by averaging treatment period PEF values and subtracting the baseline morning PEF value.

Time frame:
12 months
Reported as:
Mean · L/min
Morning Peak Expiratory Flow (PEF)
L/minSYM 160/4.5 X 2 BIDSYM 80/4.5 X 2 BIDFOR 4.5 X 2 BID
Morning Peak Expiratory Flow (PEF)19.82 ± 37.9619.61 ± 38.8315.81 ± 41.43
SecondaryEvening PEF

Change in evening PEF from baseline to the average of the randomized treatment period, as calculated by averaging treatment period PEF values and subtracting the baseline evening PEF value.

Time frame:
12 months
Reported as:
Mean · L/min
Evening PEF
L/minSYM 160/4.5 X 2 BIDSYM 80/4.5 X 2 BIDFOR 4.5 X 2 BID
Evening PEF17.62 ± 37.8617.77 ± 37.6714.08 ± 41.13
SecondaryDyspnea Symptom Scores

Change from baseline of Dyspnea symptoms evaluated using the breathlessness diary, a 5-point Likert-type scale, ranging from 0 to 4 with higher scores indicating a more severe manifestation of the Dyspnea symptom. Change from baseline was calculated by averaging treatment period Dyspnea scores and subtracting the baseline Dyspnea scores.

Time frame:
12 months
Reported as:
Mean · Scores on a scale
Dyspnea Symptom Scores
Scores on a scaleSYM 160/4.5 X 2 BIDSYM 80/4.5 X 2 BIDFOR 4.5 X 2 BID
Dyspnea Symptom Scores-0.30 ± 0.65-0.29 ± 0.70-0.24 ± 0.67
SecondaryUse of Rescue Medication

Change from baseline in the use of beta-2 agonists, as calculated by averaging treatment period inhalations per day and subtracting the baseline number of inhalations per day.

Time frame:
12 months
Reported as:
Mean · Number of inhalations
Use of Rescue Medication
Number of inhalationsSYM 160/4.5 X 2 BIDSYM 80/4.5 X 2 BIDFOR 4.5 X 2 BID
Use of Rescue Medication-1.21 ± 3.57-1.03 ± 3.74-0.28 ± 3.60
SecondarySt. George's Respiratory Questionnaire (SGRQ) Score

Change from baseline in the SGRQ overall score, as calculated by averaging treatment period SGRQ scores and subtracting the baseline SGRQ scores. The SGRQ contains 3 domains: Symptoms (distress due to respiratory symptoms, 8 questions), Activity (disturbance of physical activity, 16 questions), and Impacts (overall impact on daily life and well-being, 26 questions). Lower scores are associated with less severe symptoms.

Time frame:
12 months
Reported as:
Mean · Scores on a scale
St. George's Respiratory Questionnaire (SGRQ) Score
Scores on a scaleSYM 160/4.5 X 2 BIDSYM 80/4.5 X 2 BIDFOR 4.5 X 2 BID
St. George's Respiratory Questionnaire (SGRQ) Score-6.23 ± 14.72-5.00 ± 16.10-5.71 ± 15.31
PrimaryRate of Exacerbations Per Subject-year

Rate of exacerbations per subject-year

Time frame:
12 months
Reported as:
Number · Rate
Rate of Exacerbations Per Subject-year
RateSYM 160/4.5 X 2 BIDSYM 80/4.5 X 2 BIDFOR 4.5 X 2 BID
Rate of Exacerbations Per Subject-year0.6390.7451.029

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SYM 160/4.5 X 2 BID—79/407 (19.4%)193/407 (47.4%)
SYM 80/4.5 X 2 BID—61/408 (15%)177/408 (43.4%)
FOR 4.5 X 2 BID—73/403 (18.1%)176/403 (43.7%)
Most frequent serious events
Showing 10 of 123
Most frequent serious events
EventSYM 160/4.5 X 2 BIDSYM 80/4.5 X 2 BIDFOR 4.5 X 2 BID
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders32/40733/40834/403
Pneumonia BacterialInfections and infestations13/4074/4087/403
Atrial FibrillationCardiac disorders6/4073/4080/403
Myocardial InfarctionCardiac disorders0/4071/4083/403
BronchitisInfections and infestations0/4070/4083/403
Cardiac Failure CongestiveCardiac disorders3/4071/4080/403
Respiratory FailureRespiratory, thoracic and mediastinal disorders3/4072/4081/403
Cardiac ArrestCardiac disorders0/4071/4082/403
Cor PulmonaleCardiac disorders0/4071/4082/403
GastritisGastrointestinal disorders0/4070/4082/403
Most frequent other events
Most frequent other events
EventSYM 160/4.5 X 2 BIDSYM 80/4.5 X 2 BIDFOR 4.5 X 2 BID
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders57/40746/40868/403
HeadacheNervous system disorders56/40746/40843/403
NasopharyngitisInfections and infestations31/40735/40841/403
BronchitisInfections and infestations37/40732/40825/403
InfluenzaInfections and infestations29/40726/40825/403
Upper Respiratory Tract Infection BacterialInfections and infestations18/40723/40817/403
Back PainMusculoskeletal and connective tissue disorders21/40718/40821/403
Viral Upper Respiratory Tract InfectionInfections and infestations21/40713/40814/403
HypertensionVascular disorders21/40716/4089/403

Baseline characteristics

Age Continuous
Age Continuous(Years)SYM 160/4.5 X 2 BIDSYM 80/4.5 X 2 BIDFOR 4.5 X 2 BIDTotal
Mean63.8 ± 9.462.8 ± 9.2262.5 ± 9.3663.0 ± 9.34
Sex: Female, Male
Sex: Female, Male(Participants)SYM 160/4.5 X 2 BIDSYM 80/4.5 X 2 BIDFOR 4.5 X 2 BIDTotal
Female145144174463
Male262264229755
08

Study locations

140 sites
  • Research Site
    Jasper, Alabama, United States
  • Research Site
    Mobile, Alabama, United States
  • Research Site
    Tucson, Arizona, United States
  • Research Site
    Fort Smith, Arkansas, United States
  • Research Site
    Little Rock, Arkansas, United States
  • Research Site
    Anaheim, California, United States
  • Research Site
    Foothill Ranch, California, United States
  • Research Site
    Fullerton, California, United States
  • Research Site
    Long Beach, California, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Los Banos, California, United States
  • Research Site
    Mission Viejo, California, United States
  • Research Site
    Pismo Beach, California, United States
  • Research Site
    Rancho Cordova, California, United States
  • Research Site
    Rancho Mirage, California, United States
  • Research Site
    Riverside, California, United States
  • Research Site
    Rolling Hills Estates, California, United States
  • Research Site
    Sacramento, California, United States
  • Research Site
    San Diego, California, United States
  • Research Site
    Sepulveda, California, United States
  • Research Site
    Torrance, California, United States
  • Research Site
    Englewood, Colorado, United States
  • Research Site
    Wheat Ridge, Colorado, United States
  • Research Site
    Stanford, Connecticut, United States
  • Research Site
    Deland, Florida, United States
  • Research Site
    Opalocka, Florida, United States
  • Research Site
    Orange City, Florida, United States
  • Research Site
    Orlando, Florida, United States
  • Research Site
    Panama City, Florida, United States
  • Research Site
    Pensacola, Florida, United States
  • Research Site
    Sarasota, Florida, United States
  • Research Site
    St Cloud, Florida, United States
  • Research Site
    Augusta, Georgia, United States
  • Research Site
    Blue Ridge, Georgia, United States
  • Research Site
    Marietta, Georgia, United States
  • Research Site
    Boise, Idaho, United States
  • Research Site
    Coeur D'alene, Idaho, United States
  • Research Site
    Chicago, Illinois, United States
  • Research Site
    Council Bluffs, Iowa, United States
  • Research Site
    Witchita, Kansas, United States
  • Research Site
    Marrero, Louisiana, United States
  • Research Site
    Metairie, Louisiana, United States
  • Research Site
    Sunset, Louisiana, United States
  • Research Site
    Bangor, Maine, United States
  • Research Site
    Pittsfield, Massachusetts, United States
  • Research Site
    Waltham, Massachusetts, United States
  • Research Site
    Chesterfield, Missouri, United States
  • Research Site
    Florissant, Missouri, United States
  • Research Site
    Kansas City, Missouri, United States
  • Research Site
    St. Louis, Missouri, United States
  • Research Site
    Missoula, Montana, United States
  • Research Site
    Omaha, Nebraska, United States
  • Research Site
    Papillion, Nebraska, United States
  • Research Site
    Las Vegas, Nevada, United States
  • Research Site
    Springfield, New Jersey, United States
  • Research Site
    Bronxville, New York, United States
  • Research Site
    Elmira, New York, United States
  • Research Site
    Larchmont, New York, United States
  • Research Site
    Charlotte, North Carolina, United States
  • Research Site
    Elizabeth City, North Carolina, United States
  • Research Site
    Hickory, North Carolina, United States
  • Research Site
    Chardon, Ohio, United States
  • Research Site
    Cincinnati, Ohio, United States
  • Research Site
    Columbus, Ohio, United States
  • Research Site
    Sylvania, Ohio, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    Medford, Oregon, United States
  • Research Site
    Portland, Oregon, United States
  • Research Site
    Beaver, Pennsylvania, United States
  • Research Site
    Bensalem, Pennsylvania, United States
  • Research Site
    Downingtown, Pennsylvania, United States
  • Research Site
    Harrisburg, Pennsylvania, United States
  • Research Site
    Landsdale, Pennsylvania, United States
  • Research Site
    Philadelphia, Pennsylvania, United States
  • Research Site
    Pittsburgh, Pennsylvania, United States
  • Research Site
    Warminster, Pennsylvania, United States
  • Research Site
    Yardley, Pennsylvania, United States
  • Research Site
    East Providence, Rhode Island, United States
  • Research Site
    Charleston, South Carolina, United States
  • Research Site
    Gaffney, South Carolina, United States
  • Research Site
    Greenville, South Carolina, United States
  • Research Site
    Prosperity, South Carolina, United States
  • Research Site
    Spartanburg, South Carolina, United States
  • Research Site
    Union, South Carolina, United States
  • Research Site
    Fayetteville, Tennessee, United States
  • Research Site
    Boerne, Texas, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    McKinney, Texas, United States
  • Research Site
    San Antonio, Texas, United States
  • Research Site
    Abingdon, Virginia, United States
  • Research Site
    Spokane, Washington, United States
  • Research Site
    Tacoma, Washington, United States
  • Research Site
    9 de Julio, Buenos Aires, Argentina
  • Research Site
    Capital Federal, Buenos Aires, Argentina
  • Research Site
    Mar Del Plata, Buenos Aires, Argentina
  • Research Site
    Ramos Mejia, Buenos Aires, Argentina
  • Research Site
    Vicente Lopez, Buenos Aires, Argentina
  • Research Site
    San Miguel de Tucuman, Tucuman, Argentina
  • Research Site
    Cordoba, Argentina
  • Research Site
    Corrientes, Argentina

Showing the first 100 of 140 sites across 9 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, Fageras M. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018 Feb;6(2):117-126. doi: 10.1016/S2213-2600(18)30006-7. Epub 2018 Jan 10. PubMed 29331313 ↗
  • Jenkins CR, Postma DS, Anzueto AR, Make BJ, Peterson S, Eriksson G, Calverley PM. Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease. BMC Pulm Med. 2015 Aug 21;15:97. doi: 10.1186/s12890-015-0077-0. PubMed 26293575 ↗
  • Make BJ, Eriksson G, Calverley PM, Jenkins CR, Postma DS, Peterson S, Ostlund O, Anzueto A. A score to predict short-term risk of COPD exacerbations (SCOPEX). Int J Chron Obstruct Pulmon Dis. 2015 Jan 27;10:201-9. doi: 10.2147/COPD.S69589. eCollection 2015. PubMed 25670896 ↗
  • Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med. 2012 Feb;106(2):257-68. doi: 10.1016/j.rmed.2011.07.020. Epub 2011 Oct 26. PubMed 22033040 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2007
First posted
Jan 9, 2007
Start
Jan 2007
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
Sep 16, 2010
Last update
Sep 16, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00419744
Lead sponsor
AstraZeneca
First posted
Jan 9, 2007
Start date
Jan 2007
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
Sep 16, 2010
Last update
Sep 16, 2010

Study contacts

Christer Hultquist, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Formoterol

Start the discussion